ClinicalTrials.gg
Active, not recruitingNCT01421095Updated Oct 13, 2026

Ovarian Reserve Testing in Female Young Adult Cancer Survivors

An interventional study of recombinant FSH in Cancer and Infertility, sponsored by University of California, San Diego. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University of California, San Diego · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

Young adult cancer survivors constitute an under served population to whom fertility potential is particularly important. For female young adult patients, cancer treatment such as alkylating chemotherapy are toxic to the finite number of eggs they have, resulting in risks of infertility and premature menopause related to ovarian failure. Reproductive issues are a major concern for young cancer survivors, but one that is understudied. Young cancer survivors have few tools to measure post-treatment ovarian reserve, or the quantity and quality of remaining eggs4. Accurate determination of ovarian reserve and fertility potential would not only be an important research tool, but also directly impact clinical management. The purpose of this study is to test if basal and provocative ovarian reserve testing can predict return of menses in female young adult cancer survivors, to compare basal and provocative ovarian reserve testing results between female young adult cancer survivors and healthy controls, and to compare basal and provocative ovarian reserve testing results between female young adult cancer survivors on and off of combined estrogen and progesterone hormone products.

Participants will be asked to keep track of their periods over three months. If a participant is taking birth control pills, patches, or vaginal ring, they will asked to come off the birth control for 3 months. Participants will also be asked to undergo ovarian reserve testing by blood draws and pelvic ultrasounds at the start and end of the 3 months.

Read the detailed description

Same as brief summary

02

Conditions studied

  • Cancer
  • Infertility

Keywords

  • Fertility
  • adolescent
  • young adult
  • cancer survivors
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 34 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of California, San Diego is the lead sponsor of 980 studies on the registry; 194 are open to participants now.

Of its 113 completed or terminated interventional studies of FDA-regulated products, 71 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Postmenarchal
  • Cancer diagnosis
  • Prior exposure to gonadotoxic therapy, inclusive of chemothearpy, pelvic or total body irradiation, unilateral oophorectomy
  • A minimum of 1 year since completion of gonoadotoxic therapy
  • Intact uterus
  • At least one ovary

Exclusion criteria

Exclusion Criteria:

  • Estrogen receptor positive cancers
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Basal Testing

    Drug: recombinant FSH

Interventions

06

What researchers measure

Primary outcomes

  1. Return of menses

    Self reported via bleeding calenders

    Time frame: 3 months

Secondary outcomes

  1. Blood levels of FSH

    Time frame: 3 months

  2. Blood levels of estradiol

    Time frame: 3 months

  3. Blood levels of AMH

    Time frame: 3 months

  4. Blood levels of inhibin B

    Time frame: 3 months

07

Study locations

1 site
  • UCSD Moores Cancer Center
    San Diego, California 91351, United States
08

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Jan 2011, a primary completion of Dec 2028 and a completion of Dec 2028. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2026 → Dec 2028 and completion Dec 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2011
First posted
Aug 22, 2011
Start
Jan 1, 2011
Primary completionEst.
Dec 2028was Dec 2026
CompletionEst.
Dec 2028was Dec 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Dec 2028
Oct 13, 2026
Study completion
Dec 2026→Dec 2028
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Dec 2026→Dec 2028
    Study completion Dec 2026→Dec 2028
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT01421095
Responsible party
Hui-Chun Irene Su (Assistant Professor of Reproductive Medicine, University of California, San Diego) — Principal investigator
First posted
Aug 22, 2011
Start date
Jan 1, 2011
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

H. Irene Su, MD MSCE
principal investigator · UC San Diego

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion